TABLE 1

Demographic Characteristics and Clinical Ratings of Aβ+ and Aβ− Groups*

CharacteristicAD Aβ+ (n = 25)AD Aβ− (n = 6)PMCI Aβ+ (n = 73)MCI Aβ− (n = 114)PNC Aβ+ (n = 26†)NC Aβ− (n = 88‡)P
Baseline age (y)76.1 ± 7.481.0 ± 6.80.1574.5 ± 7.170.3 ± 8.3<0.00177.2 ± 4.677.7 ± 6.50.72
Sex (no. of men/women)13/125/10.1646/2760/540.1616/1048/400.53
No. of subjects with 0/1/2 APOE4 alleles3/16/66/0/0<0.00123/40/1084/27/3<0.00113/12/171/17/00.003
Education (y)15.4 ± 3.116.2 ± 2.90.5716.0 ± 3.016.3 ± 2.60.4016.0 ± 2.516.6 ± 3.00.40
Follow-up duration (mo)24.4 ± 3.223.4 ± 1.10.4824.4 ± 2.324.1 ± 2.30.4923.8 ± 0.623.9 ± 1.80.76
Baseline MMSE score21.7 ± 3.421.0 ± 3.60.6527.8 ± 1.828.4 ± 1.60.0228.8 ± 1.229.1 ± 1.30.25
24-mo MMSE score decrease−3.7 ± 3.1−1.3 ± 5.70.17−1.2 ± 2.3−0.2 ± 2.20.004−0.5 ± 2.0−0.4 ± 1.40.67
Baseline ADAS-Cog13 rating31.0 ± 10.030.8 ± 9.40.9716.3 ± 6.411.9 ± 5.9<0.00111.2 ± 5.79.0 ± 4.20.04
24-mo ADAS-Cog13 rating increase8.2 ± 6.36.3 ± 10.20.561.8 ± 5.1−0.5 ± 4.30.001−0.4 ± 4.60.4 ± 3.20.33
Baseline CDR-SB score5.5 ± 3.35.8 ± 1.30.851.6 ± 1.01.2 ± 0.80.0010.1 ± 0.4-.03 ± 0.70.30
24-mo CDR-SB score increase2.3 ± 2.21.8 ± 2.10.610.8 ± 1.60.01 ± 1.40.0010.4 ± 0.80.2 ± 1.10.28

  • ↵* Data are reported as mean ± SD unless otherwise indicated.

  • ↵† Ratings on ADAS-Cog13 were not available for 3 of these subjects.

  • ↵‡ Scores on MMSE and ratings on ADAS-Cog13 were not available for 5 and 6 of these subjects, respectively.